OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma
OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin
Advertisement
OncoMethylome Sciences announced that it has entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumors.
This trial will compare the current standard-of-care therapy, which is concurrent chemoradiation and adjuvant temozolomide "TMZ" (Temodar, Schering-Plough), with the standard-of-care plus bevacizumab (Avastin, Roche). All patients will be randomized to TMZ and radiotherapy or TMZ, radiotherapy and bevacizumab. OncoMethylome Sciences will receive payments for performing MGMT testing, using their patented Methylation-Specific PCR (MSP) technology, on all patients enrolled in this trial.
Mr. Luc Segers, Senior Director Business Development at OncoMethylome commented, "We are very pleased that MGMT testing will be incorporated into this study, once again demonstrating the market interest in identifying biomarkers that will lead to more personalized healthcare."
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Pepscan Therapeutics closes a Research and License Agreement aimed at the development of novel vaccines
United_States_Environmental_Protection_Agency
Antimicrobial_pharmacodynamics
Nymox Announces New Positive Results from 3 1/2 Year Study of NX-1207 for Benign Prostatic Hyperplasia
Laparoscopic_surgery
Category:Glands
ExonHit Announces Termination of Agreement to Acquire RedPath

Coffee drinking is associated with increased longevity - "It is likely that the non-caffeinated compounds were responsible for the positive relationships observed between coffee drinking, cardiovascular disease and survival"
GE Healthcare acquires bioprocessing start-up - Obtaining nanofiber-based platform purification technology for biopharmaceutical production
Evotec to Acquire Renovis - Merger to Create Emerging Pharmaceutical Company
